SCHEMBL3743985

SCHEMBL3743985

O=C(O)CCCOc1ccc2c(Cl)c(CC3CCN(C4CCCCC4)C3=O)sc2c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.41
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
DYRK1A Q13627 1/20 0.36
PLA2G2A P14555 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
ESR1 P03372 6/20 0.34
ESR2 Q92731 6/20 0.34
ENPP3 O14638 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
FABP3 P05413 2/20 0.33
FABP4 P15090 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3753388 0.89 PDE4A (0.37) HSD11B1PDE3BPDE3ADYRK1AESR1
SCHEMBL3750937 0.86 HSD11B1 (0.39) HSD11B1PDE3BPDE3ADYRK1AESR1
Hydrochloric Acid SCHEMBL3743281 0.86 HSD11B1 (0.39) HSD11B1PDE3BPDE3ADYRK1AESR1
SCHEMBL3745664 0.85 MPI (0.46) HSD11B1DYRK1AESR1ESR2CYP1A2
SCHEMBL3744013 0.84 HSD11B1 (0.42) HSD11B1DYRK1AESR1ESR2CYP1A2
SCHEMBL3740652 0.81 HSD11B1 (0.47) HSD11B1PDE3ADYRK1AESR1ESR2
SCHEMBL3747968 0.81 CYP3A4 (0.42) HSD11B1DYRK1AESR1ESR2CYP1A2
SCHEMBL3736136 0.79 HSD11B1 (0.47) HSD11B1MEN1KMT2A
SCHEMBL4698585 0.78 HSD11B1 (0.53) HSD11B1PDE3BPDE3APLA2G2ACYP1A2
SCHEMBL3554794 0.78 HSD11B1 (0.45) HSD11B1PTGDR2CYP2C9FABP3FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834194-B2 Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents ELI LILLY AND COMPANY (US) 2010-11-16 US claimed
US-20080207691-A1 Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-08-28 US claimed
EP-1830840-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2008-07-16 EP claimed
US-7834194-B2 Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents ELI LILLY AND COMPANY (US) 2010-11-16 US disclosed
US-7834194-B2 Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents ELI LILLY AND COMPANY (US) 2010-11-16 US disclosed
US-7834194-B2 Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents ELI LILLY AND COMPANY (US) 2010-11-16 US disclosed
US-20080207691-A1 Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207691-A1 Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207691-A1 Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-08-28 US disclosed
EP-1830840-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2008-07-16 EP disclosed
EP-1830840-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2008-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207691-A1 Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSD17B1, HSD17B10 HSD11B1 1/4885PDE3B 1327/4885PDE3A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.